Repeated measures of platelet MAO activity and 5-HT in a group of suicidal women

Kempen, G.M.J. Van; Notten, Pascale; Hengeveld, Michiel W.

doi:10.1016/0006-3223(92)90265-2

Cited by 23 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another possible mechanism is that low levels of monoamine oxidases (MAOs) A and B--enzymes that metabolize noradrenaline--are often, but not always, associated with suicide (Van Kempen et al 1992). Current smokers have lower levels of MAOs than never-smokers (Fowler et al 2003; Lewitzka et al 2008).…”

Section: Resultsmentioning

confidence: 99%

Smoking and suicide: A brief overview

Hughes

2008

Drug and Alcohol Dependence

215

132

View full text Add to dashboard Cite

This article provides a brief overview of the rationales, possible mechanisms and epidemiological data on the association of smoking, smoking cessation and cessation medications with suicide. Current smoking is reliably associated with suicide both in case-control and cohort studies. The three most plausible (but relatively untested) explanations for the association are that smokers have pre-existing conditions that increase their risk for suicide, smoking causes painful and debilitating conditions that might lead to suicide, and smoking decreases serotonin and monoamine oxidase levels. Stopping smoking appears to lead to major depression in some smokers; thus, it could induce suicide; however, smoking cessation has not been associated with suicide in the few studies available. Regulatory agencies have stated bupropion, rimonabant and varenicline appear to be associated with suicide; however, the data for these statements have not been presented in sufficient detail to assess their validity. Most prior data have come from post-hoc analyses. Studies that a priori focus on understanding smoking and suicide are now needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Smoking and suicide: A brief overview

Hughes

2008

Drug and Alcohol Dependence

215

132

View full text Add to dashboard Cite

show abstract

“…It is possible that with these medications individual metabolic variation and veterinary care (eg, speed to decontamination, etc) had a greater impact on the development of clinical signs than dose ingested. Individual variation in MAO activity has been demonstrated in human medicine to affect circulating concentrations of serotonin . This variability can result from individual genetic variation or diseases that affect the vascular endothelium, the site of the majority of MAO activity .…”

Section: Discussionmentioning

confidence: 99%

Retrospective evaluation of toxicosis from selective serotonin reuptake inhibitor antidepressants: 313 dogs (2005–2010)

Thomas

Lee

Hovda

2012

J Vet Emergen Crit Care

View full text Add to dashboard Cite

show abstract

“…They found decreased platelet 5‐HT content in patients with suicidal thoughts and suicide attempts. Van Kempen et al 42 . also have reported decreased platelet 5‐HT content in a group of suicidal women, although their findings do not appear to be consistent with those of Mann et al 8 …”

Section: Serotonin Studies In Plateletsmentioning

confidence: 81%

Altered Serotonin Function in Suicide

Pandey¹

1997

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Significant progress has been made in understanding psychosocial, psychological, and environmental factors associated with suicide; however, it is only recently that attention has been paid to the understanding of the neurobiology of suicide. There are several studies that implicate the serotonin (5-HT) system in suicide. Initial evidence was obtained from observations of low 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) of depressed patients with a previous history of suicide attempts. Several strategies have been used to examine the serotonergic system in suicidal behavior, which include the determination of serotonin and its metabolites in CSF and postmortem brain tissues as well as serotonin receptor subtypes in postmortem brain tissues, and in platelets of suicidal patients. The neuroendocrine strategy, often termed the "window to the brain," has been extensively used for studying the serotonergic system in suicide. This chapter will review the results obtained from neuroendocrine and serotonin studies in platelets. Initial studies in platelets focussed on determining serotonin uptake and serotonin transporter binding sites in platelets of depressed and suicidal patients. Whereas several studies have found decreased imipramine binding sites of platelets of depressed patients, imipramine binding sites in platelets of suicidal patients showed inconsistent results. Similarly, no consistent changes in 5-HT uptake have been observed in platelets obtained from suicidal patients compared to nonsuicidal patients. On the other hand, studies of platelet 5-HT2A receptors appear to be quite encouraging. Initially, several investigators indicated that they found an increase in platelet 5-HT2A receptors in depressed patients. Subsequently, it was shown that platelet 5-HT2A receptors in suicidally depressed patients were significantly higher compared to nonsuicidally depressed patients and normal control subjects. It has also been shown that platelet 5-HT2A receptors are increased in suicidal patients independent of diagnosis, similar to platelets. 5-HT2A receptors have also been shown to be increased in the postmortem brain of suicide victims by several investigators, although some investigators do not find such an increase. The neuroendocrine strategy provides an important method for studying serotonin function in the central nervous system of depressed and suicidal patents. Using a serotonergic probe of 5-HT1A receptors, several investigators examined ipsapirone-induced prolactin release in suicidal patients and did not find it different that that of control subjects. On the other hand, fenfluramine, which causes release of serotonin and blocks serotonin uptake, causes a decreased release of prolactin in depressed patients compared to normal control subjects. Furthermore it has been shown by some investigators that fenfluramine-induced prolactin release is also decreased in suicidal patients compared to normal control subjects. In summary, platelet and neuroendocrine studies have provided initial evid...

show abstract

Repeated measures of platelet MAO activity and 5-HT in a group of suicidal women

Cited by 23 publications

References 5 publications

Smoking and suicide: A brief overview

Smoking and suicide: A brief overview

Retrospective evaluation of toxicosis from selective serotonin reuptake inhibitor antidepressants: 313 dogs (2005–2010)

Altered Serotonin Function in Suicide

Contact Info

Product

Resources

About